About EmphyCorp
EmphyCorp has been granted four U.S.
patents and three additional are pending
with respect to its new drug,
"N115".
Key distinctions that set N115 apart from current treatments for pulmonary diseases are:
- There is a significant worldwide medical need and market for a safe and effective pulmonary disease therapy that can be effective as both a bronchodilator and an anti-inflammatory agent. EmphyCorp believes that N115 will prove to be a safe and effective duel acting therapy.
- N115 is a natural component of the human body and will have less side-effects than current methods of treatment for asthma and other major respiratory diseases (such as steroids or albuterol). The low side-effect profile should be especially important in children.
- The FDA has granted EmphyCorp Orphan Drug designation for a class of rare (but often fatal) pulmonary diseases known as Interstitial Lung Disease (ILD). EmphyCorp is the only company to have received such a designation by the FDA for this class of diseases. This designation attests to the FDA's recognition of N115 as one of a new class of drugs known as Reactive Oxygen Species (ROS) Antagonists, for the treatment of pulmonary disease.
- The FDA has granted EmphyCorp a second Orphan Drug designation for the use of N115 in the treatment of Cystic Fibrosis a class of pulmonary disease. EmphyCorp is the only company to have received such a designation by the FDA for this class of disease for a small molecule.
- Currently, N115 is the only known dosing method of using sodium pyruvate for respiratory diseases by inhalation into the lung i.e., by a nebulizer. This dosing method is strongly protected in the patents. Other dosing routes like oral administration, topical administration or injection are extremely unlikely to be effective in this application.
- Asthma may be triggered by gastro esophageal reflux disease (GERD).
- Acute or chronic sinusitis and allergic rhinitis may aggravate asthma.
- Sleep or nocturnal asthma is asthmatic symptoms that become more evident at night. These symptoms are probably not related to lying down or to sleep and instead probably reflect the ongoing inflammatory state of the airways.
- Hormone-related asthma may occur in some women who experience aggravation of asthma shortly before their menstrual periods.
- Use of oral contraceptives may also aggravate asthma. An overactive thyroid gland has been linked to provoking or worsening asthma; treatment of the overactive thyroid may help relieve asthma symptoms.
Estimates of the Costs of N115
production and application will make it a
cost-effective pulmonary disease treatment
on the market.
|
